Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript

Published on 8 May 2024 on Insider Monkey via Yahoo Finance

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript May 7, 2024

Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.75, expectations were $1.13. LGND isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Thank you for standing by. Our name is Benjamin and I will be your conference operator today. At this time, I would like to welcome everyone to the Ligand First Quarter 2024 Earnings Webcast. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. [Operator Instructions] Thank you. I would now like to turn the call over to Michael Jeong, Investor Relations. Please go ahead.

Read the rest of the article

NASDAQ.LGND price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

News

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript

NASDAQ.LGND price evolution

Want to become a better investor?

The past three years for Ligand Pharmaceuticals (NASDAQ:LGND) investors has not...

Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down

Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates

Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript

Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates

Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion

Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up

Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug

Corcept (CORT) Completes Enrollment in Phase II ALS Study